Healthcare Professional Check

This website is intended for diabetes healthcare professionals. Click one of the options below to access the content.

You are here

Coming Soon

Unmet Needs and Rationale for Combination Therapies for Diabetes Specialists

for Diabetes Specialists

In this course, you will learn about the rationale for adding a glucagon-like peptide-1 (GLP-1) receptor agonist to basal insulin therapy. The complementary effects of basal insulin–GLP-1 receptor agonist combination therapy will be discussed in terms of glycaemic control, change in body weight, and risk of hypoglycaemia. Sign up to the E-Alert to be updated on all new publications.

Course contents

  • Webcast

    Impact of current and emerging therapies on body weight

    • Importance of individualized treatment approach (treatment guidelines)
    • Benefits of weight loss
    • Glucose-lowering drugs associated with weight gain/weight loss
    • Emerging treatments and their effects on body weight
  • Webcast

    Rationale for basal insulin–GLP-1 RA combination

    • The synergistic effects of basal insulin and long-acting GLP-1 RA on body weight, FPG, and PPG
    • Currently available GLP-1 RAs and their clinical outcomes as co-treatments with insulin
    • The expected benefits of the basal insulin–GLP-1 RA combination
    • Benefits of fixed-ratio basal insulin–GLP-1 RA combination
  • Selected article

  • Selected article

  • Selected article

Courses are now online!

Register for the Insulin Educational program and start any available content whenever you want. You can sign up to the E-alert list to be notified when new courses or course modules are uploaded.

Search this site

Search form


Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk